|
gptkbp:instanceOf
|
gptkb:drug
small molecule
|
|
gptkbp:administeredBy
|
oral
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2012
|
|
gptkbp:ATCCode
|
L01XE17
|
|
gptkbp:brand
|
Inlyta
|
|
gptkbp:CASNumber
|
319460-85-0
|
|
gptkbp:chemicalFormula
|
C22H18N4OS
|
|
gptkbp:contraindication
|
hypersensitivity to axitinib
|
|
gptkbp:developedBy
|
gptkb:Pfizer
|
|
gptkbp:drugInteraction
|
strong CYP3A4 inducers
strong CYP3A4 inhibitors
|
|
gptkbp:eliminationHalfLife
|
2.5-6.1 hours
|
|
gptkbp:form
|
5 mg
1 mg
|
|
gptkbp:hasBoxedWarning
|
none
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
axitinib
|
|
gptkbp:KEGGID
|
D08916
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
gptkb:receptor_tyrosine_kinase
|
|
gptkbp:metabolism
|
gptkb:CYP1A2
gptkb:CYP2C19
gptkb:CYP3A4
|
|
gptkbp:molecularWeight
|
386.47 g/mol
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL521686
6450551
DB06626
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:palmar-plantar_erythrodysesthesia
nausea
diarrhea
fatigue
hypertension
weight loss
decreased appetite
dysphonia
|
|
gptkbp:storage
|
20°C to 25°C
|
|
gptkbp:target
|
gptkb:VEGFR-1
gptkb:VEGFR-2
gptkb:VEGFR-3
|
|
gptkbp:UNII
|
G34N38R2N1
|
|
gptkbp:usedFor
|
renal cell carcinoma
|
|
gptkbp:bfsParent
|
gptkb:VEGFR2
gptkb:KDR
|
|
gptkbp:bfsLayer
|
6
|